Patton Fund Management Inc. Has $2.47 Million Stake in CVS Health Corporation $CVS

Patton Fund Management Inc. decreased its position in CVS Health Corporation (NYSE:CVS) by 62.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,360 shares of the pharmacy operator’s stock after selling 58,150 shares during the quarter. Patton Fund Management Inc.’s holdings in CVS Health were worth $2,468,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd boosted its holdings in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares in the last quarter. Swiss RE Ltd. bought a new position in CVS Health during the fourth quarter valued at about $26,000. Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health in the fourth quarter worth about $28,000. Sankala Group LLC bought a new stake in shares of CVS Health during the 4th quarter worth about $28,000. Finally, Ares Financial Consulting LLC acquired a new position in shares of CVS Health during the 4th quarter valued at about $29,000. Institutional investors own 80.66% of the company’s stock.

Analyst Upgrades and Downgrades

CVS has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of CVS Health in a report on Thursday, June 11th. Barclays increased their price target on CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a report on Tuesday, May 26th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Morgan Stanley upped their price objective on shares of CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Finally, Wall Street Zen lowered shares of CVS Health from a “buy” rating to a “hold” rating in a research note on Monday. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $101.28.

CVS Health Stock Performance

NYSE CVS opened at $104.38 on Monday. The company’s fifty day moving average is $91.81 and its two-hundred day moving average is $82.44. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $106.15. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market capitalization of $133.18 billion, a price-to-earnings ratio of 45.98, a P/E/G ratio of 1.02 and a beta of 0.62.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the prior year, the business earned $2.25 earnings per share. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts forecast that CVS Health Corporation will post 7.44 EPS for the current year.

Insider Activity at CVS Health

In other news, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director directly owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,441,551 shares of company stock valued at $323,703,977. Insiders own 0.85% of the company’s stock.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.